Scout Bio Acquired by Leading Animal Health Company
French company Ceva Santé Animale announced that it is acquiring Scout Bio.
Y-Prize Goes to LilyLoop, a feminine product that captures menstrual flow data for improved diagnostics
LilyLoop, which proposed a commercial application for Penn’s biodegradeable moisture sensors, is the winner of the Mack Institute for Innovation Management’s 2024 Y-Prize Competition.
PCIV Company OmnicPath AI Published in Nature BioTechnology
OmnicPath AI specializes in developing an end-to-end workflow that integrates Spatial Transcriptomics (ST) data and high-resolution histology images to predict spatial gene expression.
The Future Applications of Penn Medicine’s mRNA Technology
Weissman has partnered in building 18 mRNA-capable Good Manufacturing Practice (GMP) sites to date across the world.
Koo and Steager’s Tooth-brushing microrobots offer even more life-changing applications
In 2024, Koo and Steager sat down with Penn Today to discuss this technology’s potential not only to brush teeth, but also to diagnose and treat infectious diseases–in teeth and beyond.
Shu Yang and Vytrina win Penn Health Tech Award and PCI’s Inventor of the Year Award
In this Penn Today article, Yang explains how her inventions begin with changes on a fundamental level that can then grow into scalable and impactful products.
Robotics Growth in Philadelphia Highlighted
The Philadelphia Business Journal recently released an article about robotics growth in Philadelphia.
Penn Spinout EpiVario Announces Acquisition of Acetyl CoA Synthetase 2 (ACSS2) Inhibitor Portfolio from Metabomed LTD
Penn spinout EpiVario, a biotech company focusing on neuroepigenetics for addiction disorders, has acquired small molecule acetyl co-A synthetase-2 inhibitor (ACSS2i) portfolio.
Four Penn Startups Make The Philadelphia Business Journal’s PHL Inno List of 2024 Startups to Watch
Baleena, BlueWhale Bio, Treeswift and Verismo were all recognized.
Penn health system profits support medical research and teaching over past decade
Penn was highlighted in the Philadelphia Inquirer for investing $2 billion in profits from its health system into medical research and physician support over the past decade.